Eftilagimod alfa (efti)
1st & 2nd line Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profileAbout Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profileAbout Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profileAbout Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profile